CN114206853A - 用于治疗的parp14的靶向蛋白质降解 - Google Patents

用于治疗的parp14的靶向蛋白质降解 Download PDF

Info

Publication number
CN114206853A
CN114206853A CN202080044704.2A CN202080044704A CN114206853A CN 114206853 A CN114206853 A CN 114206853A CN 202080044704 A CN202080044704 A CN 202080044704A CN 114206853 A CN114206853 A CN 114206853A
Authority
CN
China
Prior art keywords
alkyl
methyl
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080044704.2A
Other languages
English (en)
Chinese (zh)
Inventor
劳里·B·申克尔
梅利莎·玛丽·瓦斯宾德
凯文·韦恩·孔茨
克伦·凯来·斯温格
蒂莫西·J·N·威格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Medical Co
Original Assignee
Nippon Medical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Medical Co filed Critical Nippon Medical Co
Priority to CN202510536711.9A priority Critical patent/CN120398840A/zh
Publication of CN114206853A publication Critical patent/CN114206853A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080044704.2A 2019-06-19 2020-06-18 用于治疗的parp14的靶向蛋白质降解 Pending CN114206853A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510536711.9A CN120398840A (zh) 2019-06-19 2020-06-18 用于治疗的parp14的靶向蛋白质降解

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863357P 2019-06-19 2019-06-19
US62/863,357 2019-06-19
PCT/US2020/038377 WO2020257416A1 (en) 2019-06-19 2020-06-18 Targeted protein degradation of parp14 for use in therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510536711.9A Division CN120398840A (zh) 2019-06-19 2020-06-18 用于治疗的parp14的靶向蛋白质降解

Publications (1)

Publication Number Publication Date
CN114206853A true CN114206853A (zh) 2022-03-18

Family

ID=71527971

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080044704.2A Pending CN114206853A (zh) 2019-06-19 2020-06-18 用于治疗的parp14的靶向蛋白质降解
CN202510536711.9A Pending CN120398840A (zh) 2019-06-19 2020-06-18 用于治疗的parp14的靶向蛋白质降解

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510536711.9A Pending CN120398840A (zh) 2019-06-19 2020-06-18 用于治疗的parp14的靶向蛋白质降解

Country Status (11)

Country Link
US (2) US20220388985A1 (enExample)
EP (1) EP3986887A1 (enExample)
JP (2) JP2022537349A (enExample)
KR (1) KR20220024098A (enExample)
CN (2) CN114206853A (enExample)
AU (1) AU2020296063B2 (enExample)
BR (1) BR112021025645A2 (enExample)
CA (1) CA3142002A1 (enExample)
MA (1) MA56513A (enExample)
SG (1) SG11202112980TA (enExample)
WO (1) WO2020257416A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114890989A (zh) * 2022-05-25 2022-08-12 佛山市晨康生物科技有限公司 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用
CN116813640A (zh) * 2023-06-29 2023-09-29 成都金瑞基业生物科技有限公司 一类抑制并降解parp的化合物及应用
CN117229224A (zh) * 2022-06-07 2023-12-15 中国药科大学 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用
WO2024046366A1 (zh) * 2022-09-01 2024-03-07 浙江文达医药科技有限公司 选择性parp1抑制剂

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2941818T3 (es) * 2017-12-21 2023-05-25 Ribon Therapeutics Inc Quinazolinonas como inhibidores de PARP14
WO2022150667A1 (en) * 2021-01-08 2022-07-14 The Board Of Regents Of The University Of Texas System Nimbolide analogs and methods of use thereof
TW202241426A (zh) * 2021-01-29 2022-11-01 美商律幫治療股份有限公司 治療發炎疾病之方法
MA71624A (fr) 2022-07-29 2025-05-30 Abbvie Operations Singapore Pte. Ltd. Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
KR20250055508A (ko) 2022-07-29 2025-04-24 애브비 오퍼레이션즈 싱가포르 피티이. 리미티드 치료에 사용하기 위한 parp14의 표적 단백질 분해
WO2024251205A1 (zh) * 2023-06-06 2024-12-12 西藏海思科制药有限公司 一种喹唑啉酮衍生物及其在医药上的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106414442A (zh) * 2014-04-23 2017-02-15 因赛特公司 作为BET蛋白抑制剂的1H‑吡咯并[2,3‑c]吡啶‑7(6H)‑酮和吡唑并[3,4‑c]吡啶‑7(6H)‑酮
WO2019014429A1 (en) * 2017-07-12 2019-01-17 Dana-Farber Cancer Institute, Inc. COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508414A (ja) * 2012-01-12 2015-03-19 イエール ユニバーシティ Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
EP2890696A1 (en) * 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
EP3535265A4 (en) * 2016-11-01 2020-07-08 Arvinas, Inc. PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
EP3580212A4 (en) * 2017-02-08 2021-03-17 Dana Farber Cancer Institute, Inc. REGULATION OF CHEMERIC ANTIGEN RECEPTORS
ES2941818T3 (es) * 2017-12-21 2023-05-25 Ribon Therapeutics Inc Quinazolinonas como inhibidores de PARP14

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106414442A (zh) * 2014-04-23 2017-02-15 因赛特公司 作为BET蛋白抑制剂的1H‑吡咯并[2,3‑c]吡啶‑7(6H)‑酮和吡唑并[3,4‑c]吡啶‑7(6H)‑酮
WO2019014429A1 (en) * 2017-07-12 2019-01-17 Dana-Farber Cancer Institute, Inc. COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114890989A (zh) * 2022-05-25 2022-08-12 佛山市晨康生物科技有限公司 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用
CN114890989B (zh) * 2022-05-25 2024-03-22 广东晨康生物科技有限公司 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用
CN117229224A (zh) * 2022-06-07 2023-12-15 中国药科大学 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用
CN117229224B (zh) * 2022-06-07 2026-05-08 中国药科大学 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用
WO2024046366A1 (zh) * 2022-09-01 2024-03-07 浙江文达医药科技有限公司 选择性parp1抑制剂
CN116813640A (zh) * 2023-06-29 2023-09-29 成都金瑞基业生物科技有限公司 一类抑制并降解parp的化合物及应用

Also Published As

Publication number Publication date
JP7844707B2 (ja) 2026-04-13
MA56513A (fr) 2022-04-27
US20260125362A1 (en) 2026-05-07
EP3986887A1 (en) 2022-04-27
WO2020257416A1 (en) 2020-12-24
AU2020296063A1 (en) 2021-12-23
BR112021025645A2 (pt) 2022-02-01
AU2020296063B2 (en) 2026-01-29
KR20220024098A (ko) 2022-03-03
SG11202112980TA (en) 2021-12-30
CA3142002A1 (en) 2020-12-24
CN120398840A (zh) 2025-08-01
US20220388985A1 (en) 2022-12-08
JP2022537349A (ja) 2022-08-25
JP2025102917A (ja) 2025-07-08

Similar Documents

Publication Publication Date Title
US20260125362A1 (en) Targeted protein degradation of parp14 for use in therapy
JP7721501B2 (ja) Ｃｄ３８の阻害剤としてのヘテロ二環式アミド
KR102958021B1 (ko) 피리다지닐 티아졸카르복시아미드 화합물
KR102835667B1 (ko) Parp14 억제제로서의 퀴나졸리논
JP7777596B2 (ja) Ｃｄ３８阻害剤としてのキノリン及びアザキノリン
WO2017071516A1 (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
JP2025525031A (ja) 治療に使用するためのｐａｒｐ１４の標的化タンパク質分解
HK40085586A (en) Pyridazinyl thiazolecarboxamide compound
HK40039341A (en) Quinazolinones as parp14 inhibitors
HK40039341B (en) Quinazolinones as parp14 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220318

WD01 Invention patent application deemed withdrawn after publication